With Zurampic, FDA Again Made Do With Sorry State Of Regulatory Science In Gout

Zurampic, which AstraZeneca licensed to Ironwood, pushed the limits of FDA's tolerance of the regulatory compromises agency has had to make in gout; our Drug Review Profile shows how statistician's case against approval received serious consideration, although the agency ultimately valued consistency with previous approvals in the space.

AstraZeneca PLC subsidiary Ardea Biosciences Inc.'s gout therapy Zurampic (lesinurad) challenged FDA's regulatory flexibility when secondary clinical endpoints failed to provide the expected backup to the primary endpoint, a surrogate measure that has never been fully tested in a clinical outcomes trial.

Without the supportive scaffolding of secondary measures to provide confidence in the clinical relevance of the primary endpoint, a measure...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet